BACKGROUND AND AIMS
Red light therapy (RLT) has rapidly expanded from a niche wound-healing modality into a multibillion-dollar skincare trend marketed as a way to ‘heal the skin from within’.1-5 Across social media, medical spas, and direct-to-consumer advertising, RLT is promotedas a transformative tool for variousdermatologic conditions.6-8
METHODS
The authors performed a narrative review to identify the conditions most commonly marketed for RLT among top-selling products, characterize how these treatments are advertised, and critically compare these claims with current scientific evidence.
RESULTS
For acne, RLT is marketed as a quick and natural way to clear breakouts. Evidence demonstrates that RLT reduces inflammatory cytokines, modulates sebaceous activity, and disrupts Cutibacterium acnes colonization, resulting in modest improvements in inflammatory lesions.9 However, results take weeks to months of consistent use, contrasting with the ‘overnight clear skin’ marketing.6,7
In photoaging, RLT is advertised as a collagen-boosting alternative to injectables and surgery. Clinical studies confirm fibroblast stimulation and incremental improvements in fine lines, texture, and elasticity,1,5 but benefits are subtle, temporary without maintenance, and far less dramatic than ‘facelift in a mask’ narratives.3,6,7
For hair growth, RLT devices are promoted as effortless solutions to androgenetic alopecia. RCTs demonstrate increased hair density and shaft thickness with helmet and comb devices.5 The outcomes depend on adherence and do not match promises of ‘permanent regrowth’.3,6
CONCLUSION
Overall, while RLT demonstrates biologic plausibility and growing clinical support, commercial messaging often outpaces the evidence. Marketing frequently overstates the speed, magnitude, and consistency of results, at times portraying RLT as a broadly effective solution across multiple dermatologic conditions despite variable and condition-specific data. These claims rarely clarify which indications are well-supported versus emerging in evidence, or which patient populations may derive limited benefit. Although safety messaging, such as its UV-free nature and lack of association with skin cancer, is generally accurate, it is often presented as reassurance rather than as context for understanding both the mechanism and limitations of therapy. As with many aesthetic technologies, industry adoption and direct-to-consumer promotion have progressed more rapidly than clinical standardization. Dermatologists, therefore, play a critical role in helping patients interpret these claims, emphasizing appropriate patient selection, realistic expectations, and evidence-based use.
